1. Home
  2. BDTX vs NMAI Comparison

BDTX vs NMAI Comparison

Compare BDTX & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDTX
  • NMAI
  • Stock Information
  • Founded
  • BDTX 2014
  • NMAI 2021
  • Country
  • BDTX United States
  • NMAI United States
  • Employees
  • BDTX N/A
  • NMAI N/A
  • Industry
  • BDTX Biotechnology: Biological Products (No Diagnostic Substances)
  • NMAI Investment Managers
  • Sector
  • BDTX Health Care
  • NMAI Finance
  • Exchange
  • BDTX Nasdaq
  • NMAI Nasdaq
  • Market Cap
  • BDTX 323.2M
  • NMAI 430.5M
  • IPO Year
  • BDTX 2020
  • NMAI N/A
  • Fundamental
  • Price
  • BDTX $3.22
  • NMAI $12.91
  • Analyst Decision
  • BDTX Strong Buy
  • NMAI
  • Analyst Count
  • BDTX 4
  • NMAI 0
  • Target Price
  • BDTX $15.50
  • NMAI N/A
  • AVG Volume (30 Days)
  • BDTX 2.5M
  • NMAI 74.8K
  • Earning Date
  • BDTX 11-04-2024
  • NMAI 01-01-0001
  • Dividend Yield
  • BDTX N/A
  • NMAI 13.14%
  • EPS Growth
  • BDTX N/A
  • NMAI N/A
  • EPS
  • BDTX N/A
  • NMAI 0.64
  • Revenue
  • BDTX N/A
  • NMAI N/A
  • Revenue This Year
  • BDTX N/A
  • NMAI N/A
  • Revenue Next Year
  • BDTX N/A
  • NMAI N/A
  • P/E Ratio
  • BDTX N/A
  • NMAI $19.03
  • Revenue Growth
  • BDTX N/A
  • NMAI N/A
  • 52 Week Low
  • BDTX $1.62
  • NMAI $10.60
  • 52 Week High
  • BDTX $7.66
  • NMAI $12.55
  • Technical
  • Relative Strength Index (RSI)
  • BDTX 28.22
  • NMAI 41.18
  • Support Level
  • BDTX $3.27
  • NMAI $12.84
  • Resistance Level
  • BDTX $3.49
  • NMAI $13.00
  • Average True Range (ATR)
  • BDTX 0.25
  • NMAI 0.12
  • MACD
  • BDTX -0.01
  • NMAI -0.01
  • Stochastic Oscillator
  • BDTX 6.92
  • NMAI 12.73

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.

About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest

Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment strategy uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.

Share on Social Networks: